BioNTech mRNA Cancer Vaccine Misses Key Phase 3 Endpoint, Triggering Stock Drop

Key points

• The phase 3 portion of the Ahead-Merit trial, which tested BNT113 combined with Keytruda against Keytruda alone for HPV16-positive head and neck squamous cell carcinoma, missed its progression-free survival endpoint.
• The independent data monitoring committee advised that the trial continue to evaluate overall survival, the second primary endpoint, which could still yield a positive result if the immune response deepens over time.
• BioNTech’s stock price dropped 5% to $91.32 in premarket trading following the announcement, while Moderna’s shares also declined 3%.
• Analysts from BMO Capital Markets expressed significantly reduced confidence that BNT113 will improve overall survival, despite acknowledging that some cancer immunotherapies have succeeded on overall survival after failing on progression-free survival.
• BioNTech’s Chief Medical Officer stated that the drug is engaging its intended therapeutic mechanism, suggesting that durable benefits may emerge as immune-mediated antitumor effects build over time.

Background

In August 2026, BioNTech’s stock rose 20% following positive phase 3 data from Merck and Moderna regarding their own mRNA cancer immunotherapies, which reset expectations for the field. More recently, in October 2026, the NIH launched a public-private initiative to accelerate personalized cancer vaccine development, causing a surge in Moderna’s stock to a four-year high. This broader momentum in mRNA cancer therapies contrasts with BioNTech’s current setback, highlighting the volatility and high stakes in this sector.

Why it matters

The failure of BNT113 to meet its progression-free survival endpoint tests the resilience of the mRNA cancer vaccine platform, particularly for fixed-antigen approaches like BNT113, which differ from personalized vaccines like Moderna’s intismeran autogene. The outcome will influence investor confidence in BioNTech’s pipeline and may affect the broader market’s assessment of mRNA therapies in oncology, especially as other companies advance similar technologies. The continued tracking of overall survival offers a potential path to redemption, but the initial miss has already dented analyst confidence and impacted stock prices.

What to watch

BioNTech will continue to track patients in the Ahead-Merit trial to assess overall survival, which could still establish a positive outcome if the immune response deepens over time. The company will likely provide further updates on the trial’s progress and any potential implications for its pipeline. Investors and analysts will closely monitor the overall survival data, which is expected to be a critical determinant of BNT113’s future in head and neck cancer treatment.